TNF-receptor Associated Periodic Syndromes (TRAPS) Clinical Trial
Official title:
An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment